|Day's Range||127.29 - 128.00|
|52 Week Range||109.32 - 129.00|
|PE Ratio (TTM)||21.43|
|Dividend & Yield||3.36 (2.64%)|
|1y Target Est||N/A|
Johnson & Johnson has reached a $33 million settlement with 42 states, resolving allegations the health care giant sold numerous nonprescription medicines that didn't meet federal quality requirements ...
The $33 million settlement was announced by the attorney general on behalf of 42 states and the District of Columbia.
Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind Tylenol, Motrin, Benadryl and other over-the-counter drugs that were eventually recalled. The list includes St. Joseph Aspirin, Sudafed, Pepcid, Mylanta, Rolaids, Zyrtec, and Zyrtec Eye Drops, the Illinois attorney general said in a news release. The company's Johnson & Johnson Consumer Inc unit must also ensure that its marketing and promotional practices do not unlawfully promote over-the-counter drug products, the attorneys general said.